Compare WASH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WASH | PCRX |
|---|---|---|
| Founded | 1800 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.9M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | WASH | PCRX |
|---|---|---|
| Price | $31.04 | $26.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $30.25 | ★ $32.86 |
| AVG Volume (30 Days) | 99.4K | ★ 761.2K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $117,341,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $57.78 | $6.24 |
| Revenue Next Year | $8.69 | $9.53 |
| P/E Ratio | ★ N/A | $55.55 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $24.95 | $18.17 |
| 52 Week High | $35.27 | $27.64 |
| Indicator | WASH | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.46 | 69.80 |
| Support Level | $30.45 | $25.17 |
| Resistance Level | $31.03 | $27.16 |
| Average True Range (ATR) | 0.52 | 0.98 |
| MACD | 0.18 | 0.25 |
| Stochastic Oscillator | 95.02 | 85.16 |
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.